Quick Links

Physicians' Education Resource®, LLC, is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.

Physicians' Education Resource®, LLC, designates this enduring material for a maximum of 1.5 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity

Acknowledgement of Commercial Support

This activity is supported by educational grants from AstraZeneca and Novartis Pharmaceuticals Corporation.

Medical Crossfire®: Establishing the Role of Predictive Biomarkers and Testing Strategies for Breast Cancer Management

Release Date: August 31, 2017
Expiration Date: August 31, 2018
Media: Internet - based


Activity Overview

With improved understanding of genotypic and phenotypic methods to characterize breast cancer, clinicians have an ever-increasing ability to personalize care and individualize treatment strategies. There are several biomarkers that have been established as essential to guide the treatment of patients with breast cancer, including the estrogen and progesterone hormonal receptors, as well as HER2. In addition, BRCA mutations assist decision making concerning the potential application of PARP inhibitors for these patients. Clinical trials have also identified other biomarkers of interest, and the search for further prognostic markers and driver mutations is ongoing. It is critical for clinicians to maintain their knowledge and competence concerning the use of biomarkers and tumor testing strategies to optimize outcomes for their patients with these tumors. This Medical Crossfire® activity has been developed to provide clinicians with updates on the latest information regarding biomarkers that may shape treatment selection for their patients. Our panel of experts will discuss and debate key topics, using a balance of didactic presentation and informative interactive discussion.


Acknowledgement of Commercial Support

This activity is supported by educational grants from AstraZeneca and Novartis Pharmaceuticals Corporation.

Requirements for Successful Completion

  • You will need to login to participate in the activity.
  • Each presentation may contain an interactive question(s). You may move forward through the presentation; however, you may not go back to change answers or review videos/content until you finish the presentation.
  • At the end of the activity, “educational content/video” will be available for your reference.
  • In order to receive a CME certificate, participants must complete the activity.
  • Complete the posttest and pass with a score of 70% or higher, complete the evaluation and then click on request for credit. Participants may immediately download a CME certificate upon completion of these steps.

Target Audience

This educational activity is directed toward medical oncologists, gynecologic oncologists, and fellows who treat patients with breast cancer. Nurse practitioners, nurses, physician assistants, pharmacists, researchers, and other healthcare professionals interested in the treatment of breast cancer are also invited to participate.

Learning Objectives

At the conclusion of this activity, you should be better prepared to:

  • Evaluate current and evolving biomarkers, as well as testing methods by which these can be identified, in the setting of breast cancer
  • Examine clinical trials that have utilized biomarkers and molecular approaches in patients with breast cancer
  • Apply evidence concerning prognostic and predictive markers to inform treatment decisions in multiple lines of care for patients with breast cancer

Faculty, Staff, and Planners' Disclosures


William J. Gradishar, MD, FASCO, FACP
Betsy Bramsen Professor of Breast Oncology
Interim Chief, Division of Hematology/Oncology
Robert H. Lurie Comprehensive Cancer Center of the Feinberg School of Medicine
Northwestern University
Chicago, IL

Disclosure: No relevant financial relationships with commercial interests.


Aditya Bardia, MD, MPH
Director of Precision Medicine, Center for Breast Oncology
Attending Physician, Massachusetts General Hospital
Assistant Professor, Harvard Medical School
Boston, MA

Disclosure: Consultant: Novartis, Pfizer, Spectrum

Baljit Singh, MD
Director of Pathology
White Plains Hospital
White Plains, NY

Disclosure: Speaker’s Bureau: Genomic Health Inc.

Tiffany A. Traina, MD
Clinical Director, Breast Medicine Service
Section Head, TNBC Clinical Research Program
Associate Attending, Memorial Sloan Kettering Cancer Center
Assistant Professor, Weill Cornell College of Medicine
New York, NY

Disclosure: Grant/Research Support: Medivation, Eisai, Pfizer, Novartis, Myriad Genetics, Innocrin Pharmaceuticals, AstraZeneca. Consultant: Genentech, Eisai, Halozyme, Mundipharma, Medivation, Pfizer, AstraZeneca, Bayer, Research to Practice, Immunomedics, Merck, Puma, Astellas

The staff of Physicians' Education Resource®, LLC have no relevant financial relationships with commercial interests to disclose.

Disclosure Policy and Resolution of Conflicts of Interest (COI)

As a sponsor accredited by the ACCME, it is the policy of PER® to ensure fair balance, independence, objectivity, and scientific rigor in all of its CME activities. In compliance with ACCME guidelines, PER® requires everyone who is in a position to control the content of a CME activity to disclose all relevant financial relationships with commercial interests. The ACCME defines “relevant financial relationships” as financial relationships in any amount occurring within the past 12 months that creates a COI.

Additionally, PER® is required by ACCME to resolve all COI. PER® has identified and resolved all COI prior to the start of this activity by using a multistep process.

Off-Label Disclosure and Disclaimer

This CME activity may or may not discuss investigational, unapproved, or off-label use of drugs. Participants are advised to consult prescribing information for any products discussed. The information provided in this CME activity is for continuing education purposes only, and is not meant to substitute for the independent medical judgment of a physician or nurse relative to diagnostic, treatment, or management options for a specific patient's medical condition.

The opinions expressed in the content are solely those of the individual faculty members and do not reflect those of PER® or any of the companies that provided commercial support for this activity.

CME Provider Contact Information

Physicians’ Education Resource®, LLC
2 Clarke Drive, Suite 110
Cranbury, NJ 08512
Toll Free: 888-949-0045
Local: 609-378-3701
Fax: 609-257-0705

Hardware And Software Requirements 

Supported Browsers
Internet Explorer v.7 or greater (for Windows) | Mozilla Firefox v.2 or greater (for Windows, Mac, Linux)

Minimum System Requirements (Windows)

  • A Pentium-based PC or compatible computer
  • At least 64MB of RAM
  • Windows 95/98/NT/ME/2000/XP/Vista system software
  • Screen resolution of 1024 x 786 or larger recommended
  • PDF Reader: Adobe Reader 5.0 or higher, Foxit Reader 2.0 or likewise

Minimum System Requirements (Mac OS)

  • A PowerPC processor-based Macintosh computer
  • At least 64MB of RAM
  • Mac OS 7.5 or later
  • Screen resolution of 1024 x 786 or larger recommended
  • PDF Reader: Adobe Reader 5.0 or higher, Foxit Reader 2.0 or likewise

Become a Member

Forgot Password?
Calendar of Events
Filter By